Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0OK2N
|
|||
| Former ID |
DNCL002363
|
|||
| Drug Name |
AMG 208
|
|||
| Synonyms |
AMG-208; 1002304-34-8; AMG 208; AMG208; UNII-Y2SR66P7VM; 7-methoxy-4-((6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy)quinoline; Y2SR66P7VM; CHEBI:90626; 7-methoxy-4-[(6-phenyl[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline; 7-Methoxy-4-[(6-phenyl-1,2,4-triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline; C22H17N5O2; 7-methoxy-4-[(6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline; 7-methoxy-4-({6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl}methoxy)quinoline; Triazolopyridazine, 4; 3cd8
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 2 | [1] | |
| Company |
Amgen Thousand
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H17N5O2
|
|||
| Canonical SMILES |
COC1=CC2=NC=CC(=C2C=C1)OCC3=NN=C4N3N=C(C=C4)C5=CC=CC=C5
|
|||
| InChI |
1S/C22H17N5O2/c1-28-16-7-8-17-19(13-16)23-12-11-20(17)29-14-22-25-24-21-10-9-18(26-27(21)22)15-5-3-2-4-6-15/h2-13H,14H2,1H3
|
|||
| InChIKey |
HEAIZQNMNCHNFD-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1002304-34-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
50097515, 53786466, 57158919, 87557637, 99437088, 99444550, 103620793, 124757163, 125163967, 126731197, 131480843, 136340179, 136367390, 136920263, 137572458, 144115594, 151991713, 152258357, 160647195, 160969134, 162011566, 162205171, 163643052, 163907960, 164045110, 172912818, 174006590, 174525723, 180410153, 185998821, 198982198, 223381899, 223652598, 235263905, 244574469, 249814528, 251971305, 252109878, 252160567, 252214715
|
|||
| ChEBI ID |
CHEBI:90626
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02420587) AMG 208 Tumor Microenvironment in Metastatic Castration Resistant Prostate Cancer (mCRPC). U.S. National Institutes of Health. | |||
| REF 2 | A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors. Oncotarget. 2015 Jul 30;6(21):18693-706. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.